Clinical Trials Logo

Hypersensitivity clinical trials

View clinical trials related to Hypersensitivity.

Filter by:

NCT ID: NCT06412042 Not yet recruiting - Healthy Clinical Trials

Probiotic in Infant Growth, Allergy and Immunity Study

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

To evaluate the intervention effects of Bifidobacterium animalis subsp. lactis strain BLa80 in promoting growth and development (including gut microbiota and physical growth and development) of healthy infants and young children across different age groups, enhancing immune function, improving allergy incidence, and analyzing the safety of BLa80 in relation to infant growth and development, allergy incidence, and gut microbiota.

NCT ID: NCT06409884 Not yet recruiting - Amoxicillin Allergy Clinical Trials

Diagnosing Drug Allergy: the T is the Key

TAT
Start date: May 25, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to validate a newly developed test in the diagnosis of patients with amoxicillin allergy (i.e. T-cell activation test). The main questions the study aims to assess are the reliability and applicability of this test. Participants will be asked to visit the hospital 1, 3 or 5 times during which blood is collected and when applicable, allergy skin testing is performed.

NCT ID: NCT06406114 Not yet recruiting - Clinical trials for Drug Hypersensitivity

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

DACAT
Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

NCT ID: NCT06401408 Not yet recruiting - Allergy Clinical Trials

Effect of Virtual Reality Headsets on Fear Anxiety and Physiological Parameter in Skin Prick Test

Start date: June 20, 2024
Phase:
Study type: Observational

The goal of this clinical trial is determine the effect of virtual reality headsets on pain, anxiety, fear and physiological parameters in children aged 4-7 years who undergoing skin prick test. The main questions it amis to answer are: Virtual reality headsets effect on the pain that during the procedure Virtual reality headsets effect on the anxiety that occurs during the procedure Virtual reality headsets effect on the fear that occurs during the procedure Virtual reality headsets effect on physiological parameters (heart rate, blood pressure, respiratory rate) during the procedure

NCT ID: NCT06399601 Not yet recruiting - Drug Allergy Clinical Trials

A Training Program of Drug Allergy for Healthcare Professionals

Start date: December 9, 2024
Phase: N/A
Study type: Interventional

Drug allergy is often under-recognized, yet over- (mistakenly) diagnosed, especially in Hong Kong. There is also a dire shortage of allergy specialists and facilities to tackle the overwhelming drug allergy pandemic. Fortunately, when trained, non-specialist physicians and nurses have demonstrated comparable capabilities in drug allergy evaluation compared to specialists. To potentially promote and propagate the role of non-specialist physicians and nurses toward drug allergy care, the investigators propose a study to investigate the impact of an intensive and focused drug allergy educational course conducted at the University of Hong Kong.

NCT ID: NCT06395272 Not yet recruiting - Stroke Clinical Trials

Effects of Proprioceptive Sensitivity Stimulation Via the SURA Electrodevice on Kinematics, Kinetics and Spatiotemporal Parameters of Gait.

Start date: May 5, 2024
Phase: N/A
Study type: Interventional

Recovery of function in people with central nervous system (CNS) injury after stroke is very much like a relearning process that takes advantage of preserved sensorimotor circuits. Relearning can be optimised by providing appropriate proprioceptive (or deep sensory) information to the spinal cord with the aim of maximally engaging the preserved neural circuits. The development of the SURA electrodevice offers this sensitive input mechanism, within the Botton Up therapies. And through research on its use, the impact on the different dimensions related to gait and its components, and the translation to the functional reality of the person, will be evaluated.

NCT ID: NCT06392841 Not yet recruiting - BRCA2 Gene Mutation Clinical Trials

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

HARMONY
Start date: December 2024
Phase: Phase 2
Study type: Interventional

This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.

NCT ID: NCT06392685 Not yet recruiting - Hypersensitivity Clinical Trials

Composite Repair Using Silane Coupling Agent

Start date: July 2024
Phase: N/A
Study type: Interventional

Evaluation the influence of the use of silane coupling agent application as a separate step versus application of silane or acid resistance silane containing adhesives on the clinical performance of repaired posterior resin composite restorations according to Modified United States Public Health Service (USPHS) criteria over one year.

NCT ID: NCT06330974 Not yet recruiting - Asthma Clinical Trials

Allergy, Asthma, and Atopic Eczema in Finland

FinnATOPY
Start date: October 2024
Phase:
Study type: Observational [Patient Registry]

The summary is available at --> https://www.finnatopy.fi/summary

NCT ID: NCT06320951 Not yet recruiting - Obesity Clinical Trials

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

VITAL-IMPACT
Start date: May 1, 2025
Phase: Phase 2
Study type: Interventional

This study investigates the potential of vericiguat, a soluble guanylate cyclase stimulator, to improve cardiometabolic health in obese Black individuals with insulin resistance by directly enhancing cyclic guanosine monophosphate (cGMP) activity. Given that this population has been shown to have lower cGMP activity and the association of lower cGMP activity with increased cardiometabolic disease risk, the proposed study hypothesizes that augmenting cGMP activity in obese individuals will improve insulin sensitivity and energy expenditure. This study is a placebo-controlled randomized trial involving 200 Black obese participants with insulin resistance, assessing the effects of vericiguat on insulin sensitivity, resting, and exercise-induced energy expenditure over 12 weeks. Additionally, it will explore changes in brown adipose tissue and gene expression related to energy metabolism in white adipose tissue, aiming to provide insights into how increasing cGMP activity may improve cardiometabolic health in Black obese individuals.